claim: modified vaccinia ankara based sars-cov-2 vaccine lacking full-length spike induces strong neutralizing antibody response
evidence_1: following immunizations with mva/s or mva/s1, both spike protein recombinants induced strong igg antibodies to purified full-length sars-cov-2 spike protein.", "these results demonstrate mva/s is a potential vaccine candidate against sars-cov-2 infection.", "the mva/s induced a robust antibody response to purified rbd, s1 and s2 whereas mva/s1 induced an antibody response to the s1 region outside of the rbd region.")